Publications by authors named "Matthieu Ruffin"

Claim this Profile
S
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Marcello D Bronstein, Maria Fleseriu, Sebastian Neggers, Annamaria Colao, Michael Sheppard, Matthieu Ruffin

BMC Endocr Disord· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Michael Sheppard, Marcello D Bronstein, Pamela Freda, Omar Serri, Laura De Marinis, Matthieu Ruffin

Pituitary· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Michael Sheppard, Marcello D Bronstein, Pamela Freda, Omar Serri, Laura De Marinis, Matthieu Ruffin

Pituitary· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Stephan Petersenn, Andrew J Farrall, Christophe De Block, Shlomo Melmed, Jochen Schopohl, Matthieu Ruffin

Pituitary· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
Georg Golor, Ke Hu, Matthieu Ruffin, Alexandra Buchelt, Emmanuel Bouillaud

Drug Des Devel Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
Hartmut Dietrich, Ke Hu, Matthieu Ruffin, Dongweon Song, Emmanuel Bouillaud

Eur J Endocrinol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.
Yves Horsmans, Ke Hu, Matthieu Ruffin, Ying Wang, Dongweon Song

J Clin Pharmacol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis